Lelgemann M - Search Results

1

Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.

Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Schmucker C, et al. Among authors: lelgemann m. Br J Ophthalmol. 2011 Mar;95(3):308-17. doi: 10.1136/bjo.2009.178574. Epub 2010 Oct 22. Br J Ophthalmol. 2011. PMID: 20971791 Review.

2

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Schmucker C, Antes G, Lelgemann M. Schmucker C, et al. Among authors: lelgemann m. Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Surv Ophthalmol. 2009. PMID: 19818262 Review. No abstract available.

3

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.

Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Schmucker C, et al. Among authors: lelgemann m. Curr Opin Ophthalmol. 2010 May;21(3):218-26. doi: 10.1097/ICU.0b013e3283386783. Curr Opin Ophthalmol. 2010. PMID: 20393293 Review.

4

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK. Schmucker C, et al. Among authors: lelgemann m. PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22880086 Free PMC article. Review.

5

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Schmucker C, Antes G, Lelgemann M. Schmucker C, et al. Among authors: lelgemann m. Graefes Arch Clin Exp Ophthalmol. 2010 Mar;248(3):451-2; author reply 453-4. doi: 10.1007/s00417-009-1249-5. Epub 2009 Dec 10. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20012081 No abstract available.

6

[Clinical guidelines. What do doctors and patients get from them].

Lelgemann M, Lang B, Kunz R, Antes G. Lelgemann M, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Feb;48(2):215-20. doi: 10.1007/s00103-004-0982-5. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005. PMID: 15726463 German.

7

[Randomised controlled trials (RCTs)].

Windeler J, Antes G, Behrens J, Donner-Banzhoff N, Lelgemann M. Windeler J, et al. Among authors: lelgemann m. Z Evid Fortbild Qual Gesundhwes. 2008;102(5):321-5. doi: 10.1016/j.zefq.2008.05.002. Z Evid Fortbild Qual Gesundhwes. 2008. PMID: 19006920 German.

8

Unsustainable claims.

Lelgemann M, Wild C, Antes G, Edler L, Ernst E, Gärtner J, Schmacke N. Lelgemann M, et al. Dtsch Arztebl Int. 2015 Jan 5;112(1-2):10-1. doi: 10.3238/arztebl.2015.0010b. Dtsch Arztebl Int. 2015. PMID: 25613449 Free PMC article. No abstract available.

9

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Eyding D, et al. Among authors: lelgemann m. BMJ. 2010 Oct 12;341:c4737. doi: 10.1136/bmj.c4737. BMJ. 2010. PMID: 20940209 Free PMC article. Review.

10

[Evidence-based guidelines--what is the present situation?].

Kunz R, Lelgemann M, Schneider M. Kunz R, et al. Among authors: lelgemann m. Z Rheumatol. 2002;61 Suppl 2:II/10-3. doi: 10.1007/s00393-002-1203-y. Z Rheumatol. 2002. PMID: 12491116 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters